Multiple Myeloma
Key Points
Key Points
The estimated number of deaths from multiple myeloma in 2018 is 12,770, representing 2.1% of all cancer deaths.
Despite significant advances and improvements in overall survival, multiple myeloma remains incurable and additional treatments are needed.
The median survival is just over 5 years and most patients receive 4 or more different lines of therapy throughout their disease course.
Treatment
...eatment
...nsplant Eligible...
...be referred to a transplant center to...
...onologic age and renal function shou...
...optimal regimen and number of cycles rema...
...splant should be offered to all transplant...
...ociated with stem cell toxicity, such as melphala...
...e stem cell collection (sufficient for more than...
...of minimal response required to pro...
...h-dose melphalan is the recommended conditionin...
...gous SCT should not be routinely r...
...e or delayed SCT may be used as co...
...splant for multiple myeloma is not routinely...
...onsolidation therapy is not routinely rec...
...ide maintenance therapy should be r...
...tients intolerant of or unable to receive...
...high-risk patients, maintenance therapy...
...here is insufficient evidence to make m...
...ality and depth of response should be...
...al of initial therapy for transplan...
...nded that depth of response be assessed wit...
...y low dose CT scan has been shown to be superior...
...ant Ineligible...
...t recommendations for patients with mult...
...treatment for patients with multiple myeloma who a...
...therapies for patients with multiple mye...
...cians/patients should balance the potential...
...s therapy should be offered over fixed dur...
...l of initial therapy for transplant in...
...of response for all patients should...
...is insufficient evidence to support chan...
...tion of therapy, one should define patient spec...
...nded that patients be monitored cl...
...elapsed Disease
...t for biochemically relapsed myelom...
...cally relapsed patients with symptoms due to m...
...riplet therapy should be administered on firs...
...f relapsed multiple myeloma may be continued u...
...should be taken into consideration when sel...
...m cell transplantation, if not recei...
...us of the patients should be assess...
...essment at the time of relapse should be perfo...
...ssessment of other risk factors such as renal...
...ith genetic high-risk disease a triplet...
...ents with renal insufficiency, drugs sh...
...ents with plasma cell leukemia or extra medu...
...IMWG revised response criteria should be used for...
...surable parameters need to be followed...
...es excluding marrow and imaging should be con...
...nse assessment should be performed after...
...1. Algorithm On Management of Patients wi...
...s Used in the Management of Patients With M...
...iagnostic Criteria for Active Multiple Mye...
...Revised International Staging System (R-ISS)Havi...
...arison of Select Risk Prediction Models Relevan...
...esponse CriteriaHaving trouble viewing table? Exp...
...le 6. Estimated Cost of Drugs for M...